|
KMID : 0911820200210010006
|
|
Korean Journal of Headache
2020 Volume.21 No. 1 p.6 ~ p.13
|
|
|
Calcitonin Gene-Related Peptide Antibodies: New Era for Migraine Prophylaxis
|
|
Kim Byung-Kun
|
|
|
Abstract
|
|
|
|
Migraine is a disabling neurologic disease characterized by severe, intermittent headaches with bothersome associated symptoms. According to the Global Burden of Diseases 2016, migraine is the second leading cause of years lived with disability. Despite the availability of preventive medications for migraine, many patients do not respond to these treatments or are unable to tolerate them. Therefore, more effective, and better tolerated treatments may help improve patients’ quality of life. Development of medications targeting calcitonin gene-related peptide (CGRP) or its receptor has heralded in the new era for the treatment of migraine. Extensive basic and clinical scientific investigation has provided strong evidence that CGRP has a key role in migraine. This evidence led to the development of monoclonal antibodies (mAbs) targeting either CGRP ligand (fremanezumab, galcanezumab, and eptinezumab) or its receptor (erenumab). These drugs are approved by the US Food and Drug Administration (FDA) since 2018. Because CGRP mAbs act directly on the migraine pathophysiology, they have advantages over conventional treatments not only in effect but also in adverse effects. Galcanezumab was approved by Korea FDA in September 2019. I will summarize the history of development of CGRP mAbs in migraine, the results of clinical trials, and clinical application of CGRP mAbs in migraine management.
|
|
|
KEYWORD
|
|
|
Calcitonin gene-related peptide, Migraine, Monoclonal antibodies
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|